ADVERTORIAL
Investing in the future of medicine Take a look at how HESTA is investing in companies that are revolutionising medicine.
At HESTA, we want to invest in companies that
VAXXAS
earn strong returns for our members and also improve the wellbeing and livelihood of all people. To do this, we often look beyond the stock exchange and invest in private companies. These companies give our members access to unique investment opportunities, which they may be unaware of or don’t have the scale to access on their own. Brandon Capital Partners is just one example of how HESTA provides value to members. Brandon Capital is a specialist fund manager that invests in promising biomedical opportunities that can be truly life changing for patients. But this work
Vaxxas is an Australian biotechnology company developing novel technology that enables needlefree vaccination. This allows you to place a patch on your arm for a few seconds and then — you’re vaccinated! The applicator will revolutionise the logistics of vaccinations, making it possible to complete wide-scale vaccinations across the globe.
goes beyond treating patients: Brandon Capital also invests in vaccine innovation, from which
in clinical studies to generate potent immune responses. In fact, a recent study demonstrated that the HD-MAP required only 1/6 of the vaccine dose to generate a comparable immune response to that of a full dose of vaccine by needle/syringe
everyone benefits.
“Brandon Capital invests in promising biomedical opportunities… which can be truly life changing for patients.”
“The applicator will revolutionise the logistics of vaccinations, making it possible to complete wide-scale vaccinations across the globe.” The Vaxxas technology, known as a High-Density Microarray Patch (HD-MAP), has been shown
injection. This means the potential scalability of vaccinations could be six times greater! What’s more, HD-MAP vaccines do not require refrigeration, enabling rapid distribution using conventional delivery services. Unlike a needle or syringe, the HDMAP is easy to apply, with clinical studies currently
Let’s take a look at some of the exciting projects currently in Brandon Capital’s portfolio (and your
underway to demonstrate self-administration. So, when you consider the challenges of a vaccine
portfolio with HESTA).
rollout across countries with high-populations and challenging geographical landscapes, the Vaxxas HDMAP holds enormous value.
64
The Health Advocate • MAY 2021
